GlycoMimetics amends merger; $200M financing now pre-closing Crescent securities

CRESCENT BIOPHARMA, INC.

Ownership split unchanged: GLYC holders ~3.10%, Crescent ~96.90% after close.
Exchange ratio ~14.9149 Crescent shares per GLYC share; based on Sep 30 caps.
A&R Purchase Agreement: $200M Crescent securities purchased pre-closing, replacing post-closing GLYC financing.
Amendment adjusts filings; S-4 registration statement and company stockholder approval sequence updated.
Condition: GLYC net cash at closing must be ~$1.8M.

item 1.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001558370-25-001016
form_type: 8-K
ticker: CBIO
cik: 0001253689
company_name: CRESCENT BIOPHARMA, INC.
filed_at: 2025-02-14T23:59:59+00:00
discovered_at: 2026-05-14T18:03:03.145910+00:00
generated_at: 2026-05-26T19:24:21.078364+00:00
sec_items: ["1.01", "9.01"]
event_type: m_and_a
sentiment: neutral
materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001558370-25-001016
json_url: https://secwatch.observer/filing/0001558370-25-001016.json
markdown_url: https://secwatch.observer/filing/0001558370-25-001016.md
text_url: https://secwatch.observer/filing/0001558370-25-001016.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837025001016/0001558370-25-001016-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1253689/000155837025001016/glyc-20250214x8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001558370-25-001016

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.